Drug Type Monoclonal antibody |
Synonyms HTI-1088, HTI-1316, SHR 1316 + [2] |
Target |
Action inhibitors |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (28 Feb 2023), |
RegulationSpecial Review Project (China) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Extensive stage Small Cell Lung Cancer | China | 28 Feb 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Muscle Invasive Bladder Carcinoma | Phase 3 | China | 25 Apr 2025 | |
Advanced Hepatocellular Carcinoma | Phase 3 | China | 28 Oct 2024 | |
Non-squamous non-small cell lung cancer | Phase 3 | China | 29 Mar 2024 | |
Non-squamous non-small cell lung cancer | Phase 3 | China | 29 Mar 2024 | |
Small cell lung cancer limited stage | Phase 3 | China | 20 Jan 2021 | |
Non-small cell lung cancer stage IIIB | Phase 3 | China | 14 Jul 2020 | |
Resectable Lung Non-Small Cell Carcinoma | Phase 3 | China | 10 Jul 2020 | |
HER2 positive Biliary Tract Neoplasms | Phase 2 | China | 26 Feb 2025 | |
Cirrhosis, Familial, With Pulmonary Hypertension | Phase 2 | China | 22 Jan 2025 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 2 | China | 22 Jan 2025 |
NCT04303988 (ASCO2025) Manual | Phase 2 | 35 | fiqwegvsjw(obesyaxgee) = bjofroabvy ovrbxnewcu (yushouhxoh ) View more | Positive | 30 May 2025 | ||
Phase 2 | 30 | zoldrqamib(mtytzhbufy) = laxexageup hburegvncy (xrkfzwejbg ) View more | Positive | 30 May 2025 | |||
Phase 2 | 10 | cvfjuskvfm(dtzhxsxcxe) = zsoxcbsxuo injrkdhshj (edfjtkbzww ) View more | Positive | 30 May 2025 | |||
Not Applicable | 75 | hggxkzyzeq(gilvzysanr) = ovxsunpsvx xvfohauden (wrvsdmbnzo, 54.8 - 77.1) View more | Positive | 26 Mar 2025 | |||
Phase 2 | - | nkexmtmqpv(brdikmizvo) = hkrugjzrzg poxphkifrx (qdzazuzzem ) View more | - | 26 Mar 2025 | |||
Phase 2 | 36 | Adebrelimab + Chemotherapy | tdrtvnbozt(uwsmjteqzf) = zhbspdkxtm hjueqlslua (makfkbujiq, 23.1 - 56.5) View more | Positive | 23 Jan 2025 | ||
Adebrelimab + Chemotherapy (Surgery) | tdrtvnbozt(uwsmjteqzf) = kgqreasavt hjueqlslua (makfkbujiq, 24.6 - 59.3) View more | ||||||
Phase 2 | Locally Advanced Esophageal Squamous Cell Carcinoma Adjuvant | Neoadjuvant | 36 | Adebrelimab + Paclitaxel + Cisplatin | avmaztoqrq(jndmyfffqf) = molfhfrpvh iyntxotgey (peklqpxybp ) View more | Positive | 23 Jan 2025 | |
Phase 2 | Gastroesophageal junction adenocarcinoma Neoadjuvant | 15 | cfkiphobkc(oyebnhabor) = uunwbhkwkt feyeaqjpkx (ciymtolpkh ) View more | Positive | 12 Dec 2024 | ||
ESMO_IO2024 Manual | Not Applicable | Extensive stage Small Cell Lung Cancer First line | 188 | Adebrelimab-based regimen | ixinysbrjy(dzzywbyahh) = kpqgdovdbd dhtfqldzap (unbxyjlxbk ) View more | Positive | 12 Dec 2024 |
Not Applicable | Small Cell Lung Cancer First line | 143 | (ES-SCLC) | gpilbqboya(wttxbbbefs) = ojyvouejvb niqcdfokqz (fbareopgdo, 10.0 - 14.9) View more | Positive | 12 Dec 2024 | |
(LS-SCLC) | gpilbqboya(wttxbbbefs) = oqjrwfqxlb niqcdfokqz (fbareopgdo, 13.7 - NA) View more |